【同和药业：公司获得塞来昔布欧洲药典适应性证书】同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。

金融界2025-02-05

同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2509477119?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-05 17:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509477119","market":"sh","top_or_hot":-1,"title":"【同和药业：公司获得塞来昔布欧洲药典适应性证书】同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。","media":"金融界","content":"<div>\n<p>同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/02/05172947962229.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【同和药业：公司获得塞来昔布欧洲药典适应性证书】同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【同和药业：公司获得塞来昔布欧洲药典适应性证书】同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-05 17:29 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/02/05172947962229.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/02/05172947962229.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/02/05172947962229.shtml","article_id":"2509477119","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509477119","pubTimestamp":1738747741,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300636":"同和药业","BK0239":"医药制造"},"translate_title":"[Tonghe Pharmaceutical: The company obtained the European Pharmacopoeia Adaptability Certificate of Celecoxib] Tonghe Pharmaceutical announced that the company recently received the European Pharmacopoeia Adaptability Certificate of Celecoxib (Process II) issued by the European Medicines Quality Agency (EDQM) (CEP). This certificate marks that the company's celecoxib (Process II) API has obtained the qualification to enter the European market, which will play a positive role in the company's further expansion of international market business.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300636":1,"CEP":1},"content_text":"同和药业公告，公司近日收到欧洲药品质量管理局（EDQM）颁发的塞来昔布（工艺II）欧洲药典适应性证书（CEP）。该证书标志着公司塞来昔布（工艺II）原料药获得了欧洲市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2509477119","isCrawlerRequest":true}